News
CHMP Recommend Baricitinib for Approval in Europe
Eli Lilly and Company announced last friday that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion, recommending the approval of baricitinib for the treatment of adults with moderate to severely active rheumatoid arthritis (R
A Link Between Periodontal Disease and Rheumatoid Arthritis
Research from Johns Hopkins reports that rheumatoid arthritis (RA) patients with periodontitis exhibited patterns of autoantigen hypercitrullination similar to that seen in RA. Results published in Science Translational Medicine showed that Aggregatibacter actinomycetemcomitans can produce hypercitrullination of patient neutrophils, indicating its possible role in triggering RA. (Citation source: http://buff.ly/2hZTBG8)
BEST-D Trial: Higher Doses of Vitamin D may be Required for Optimal Osteoporosis Prevention
Osteoporosis is a major public health problems and is associated with a high burden of fractures and subsequent increased mortality.
Risk of GI Perforations on Biologics
Gastrointestinal perforation is a rare but serious complication that RA patients may be at particular risk for.
Osteoporosis 2016 Year in Review - No new drug approvals, and a crisis in care
No new osteoporosis drugs hit the market this year, but two are progressing through the development pipeline and are showing promise.
Female Physicians are Better in Death, Hospital Readmission Stats
Do hospitalized Medicare beneficiaries treated by female internists have lower rates of 30-day mortality and hospital readmission than those patients treated by men? A new study published online by JAMA Internal Medicine suggests that they do.
RheumNow Week in Review – 16 December 2016
Dr. Jack Cush reviews highlights from this week on RheumNow.com
EULAR 2016 Recommendations on Early Arthritis
Combe and leading European rheumatologist have published an update to the 2007 European League Against Rheumatism (EULAR) recommendations for management of early arthritis.
Lupus May Be at Increased Risk for Dementia
Neuropsychiatric manifestations of systemic lupus erythematosus (SLE) may occur in up to half of patients in their lifetime.
However, dementia is often not reported or studied in cohorts with neurologic disease in lupus.
Supreme Court Declines Biosimilar Patent Dispute
The U.S. Supreme Court has declined to hear a case over whether companies that make biosimilar drugs must wait six months after federal approval before they bring them to the market.
Random Drug Levels and Anti-Drug Antibodies Predict Rheumatoid Outcomes
Researchers from Manchester, UK have reported the results of their BRAGGSS study showing that certolizumab (CZP) random drug levels and anti-drug antibody (ADAbs) levels can predict optimal outcomes in CZP treated rheumatoid arthritis patients.
